Omeros Corporation (Nasdaq: OMER) today announced that two posters directed to zaltenibart (OMS906), Omeros’ investigational inhibitor of MASP-3, the key and most proximal activator of the alternative ...
Dana-Farber Cancer Institute researchers are breaking new ground in the fight against systemic mastocytosis, a rare and heterogeneous condition that is often challenging for clinicians to accurately ...